SHANGHAI – Hangzhou-based Ascletis Inc. is aiming for a home turf advantage with its interferon-free regimen for chronic hepatitis C, having submitted investigational new drug applications to both the Mainland Chinese and Taiwanese Food and Drug Administrations.